ZYME · Insider Trading
Zymeworks Inc.
Every open-market purchase and sale reported by ZYME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Adam Schayowitz | EVP, Head of R&D | MIXED | +23,205 | −$357.56K |
| 2026-07-06 | Mark Hollywood | EVP & Chief Operating Officer | A | +939 | +$20.86K |
| 2026-05-15 | Paul R Schneider | EVP, General Counsel | A | +297,000 deriv. | — |
| 2026-04-10 | Adam Schayowitz | See Remarks | A | +193,000 deriv. | — |
| 2026-04-10 | Scott Platshon | EVP, Chief Business Officer | A | +193,000 deriv. | — |
| 2026-04-07 | Kristin Stafford | EVP, Chief Financial Officer | A | +347,000 deriv. | — |
| 2026-01-13 | Brian N Cherry | Director | A | +38,400 deriv. | — |
| 2026-01-13 | Mark Hollywood | EVP & Chief Operating Officer | MIXED | +11,546 | −$138.76K |
| 2026-01-12 | Carlos Campoy | Director | A | +19,200 deriv. | — |
| 2026-01-12 | Alessandra Cesano | Director | A | +19,200 deriv. | — |
| 2026-01-12 | Paul Andrew Moore | Chief Scientific Officer | MIXED | +8,106 | −$216.76K |
| 2026-01-12 | Robert E Landry | Director | A | +19,200 deriv. | — |
| 2026-01-12 | Susan Mahony | Director | A | +19,200 deriv. | — |
| 2026-01-12 | Kelvin Neu | Director | A | +19,200 deriv. | — |
| 2026-01-12 | Kenneth Galbraith | Chair & CEO | MIXED | +33,576 | −$689.82K |
| 2026-01-12 | Gregory Austin Ciongoli | Director | A | +19,200 deriv. | — |
| 2026-01-12 | Jeffrey T L Smith | EVP & Chief Medical Officer | MIXED | +8,356 | −$211.09K |
| 2026-01-07 | Leone D Patterson | EVP, Chief Bus & Fin Officer | A | +459 | +$4.84K |
| 2026-01-05 | Kenneth Galbraith | Chair & CEO | MIXED | +59,991 | −$1.36M |
| 2026-01-05 | Jeffrey T L Smith | EVP & Chief Medical Officer | MIXED | +9,462 | −$264.47K |
| 2026-01-05 | Paul Andrew Moore | Chief Scientific Officer | MIXED | +17,058 | −$504.70K |
| 2025-12-22 | Kenneth Galbraith | Chair & CEO | MIXED | +52,472 | −$1.28M |
| 2025-08-12 | Robert E Landry | Director | A | +62,000 deriv. | — |
| 2025-08-12 | Gregory Austin Ciongoli | Director | A | +415,000 | +$4.99M |
| 2025-06-27 | Oleg Nodelman | Director | MIXED | +10,172,878 | −$25 |
| 2025-05-19 | Oleg Nodelman | Director | Buy | +110,842 | +$1.27M |
| 2025-04-18 | Oleg Nodelman | Director | Buy | +257,426 | +$2.91M |
| 2025-04-07 | Oleg Nodelman | Director | Buy | +634,416 | +$7.25M |
| 2025-04-02 | Oleg Nodelman | Director | Buy | +254,830 | +$2.99M |
| 2025-03-27 | Oleg Nodelman | Director | Buy | +194,698 | +$2.45M |
| 2025-03-24 | Oleg Nodelman | Director | Buy | +254,396 | +$3.29M |
| 2025-03-19 | Oleg Nodelman | Director | Buy | +456,926 | +$5.73M |
| 2025-03-13 | Oleg Nodelman | Director | Buy | +2,163,960 | +$26.24M |
| 2025-01-21 | EcoR1 Capital, LLC | Director | Buy | +141,429 | +$1.96M |
| 2025-01-15 | EcoR1 Capital, LLC | Director | Buy | +167,654 | +$2.28M |
| 2025-01-10 | Jeffrey T L Smith | EVP & Chief Medical Officer | A | +132,000 deriv. | — |
| 2025-01-10 | Leone D Patterson | EVP, Chief Bus & Fin Officer | A | +132,000 deriv. | — |
| 2025-01-10 | EcoR1 Capital, LLC | Director | Buy | +225,119 | +$2.97M |
| 2025-01-10 | Paul Andrew Moore | Chief Scientific Officer | A | +132,000 deriv. | — |
| 2025-01-10 | Kenneth Galbraith | Chair & CEO | A | +480,000 deriv. | — |
| 2025-01-06 | Paul Andrew Moore | Chief Scientific Officer | MIXED | +15,966 | −$316.39K |
| 2025-01-06 | Jeffrey T L Smith | EVP & Chief Medical Officer | MIXED | +8,890 | −$165.81K |
| 2025-01-06 | Kenneth Galbraith | Chair & CEO | MIXED | +57,041 | −$855.02K |
| 2025-01-02 | EcoR1 Capital, LLC | Director | Buy | +363,369 | +$5.32M |
| 2024-12-27 | EcoR1 Capital, LLC | Director | Buy | +130,309 | +$1.88M |
| 2024-12-26 | EcoR1 Capital, LLC | Director | Buy | +1,254,808 | +$17.54M |
| 2024-12-23 | EcoR1 Capital, LLC | 10%+ Owner | Buy | +5,086,521 deriv. | — |
| 2024-12-12 | Derek John Michael Miller | Director | A | +31,000 deriv. | — |
| 2024-12-12 | Neil Gallagher | Director | A | +31,000 deriv. | — |
| 2024-12-12 | Nancy Davidson | Director | A | +31,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Oleg Nodelman | Director | 22,970,388 | $657.07M |
| EcoR1 Capital, LLC | Director | 15,720,161 | $449.68M |
| Gregory Austin Ciongoli | Director | 493,500 | $14.12M |
| Kenneth Galbraith | Chair & CEO | 257,266 | $7.36M |
| Mark Hollywood | EVP & Chief Operating Officer | 133,852 | $3.83M |
| Paul Andrew Moore | Chief Scientific Officer | 48,497 | $1.39M |
| Adam Schayowitz | EVP, Head of R&D | 37,037 | $1.06M |
| Jeffrey T L Smith | EVP & Chief Medical Officer | 36,018 | $1.03M |
| Troy Cox | Director | 7,500 | $214.54K |
| Leone D Patterson | EVP, Chief Bus & Fin Officer | 459 | $13.13K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZYME quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.